CANSINOBIO (06185) Income Statement & Earnings

28.180
+1.820+6.90%

15min DelayNot Open Sep 21 16:08 CST

6.96BMarket Cap149.10P/E (TTM)

CANSINOBIO (06185) Income Statement

Cumulative·All

YOY

Hide blank lines

Currency: CNY

2026/H1

2026/Q1

2025/FY

2025/Q9

2025/H1

2025/Q1

2024/FY

2024/Q9

2024/H1

2024/Q1

2023/FY

2023/Q9

2023/H1

2023/Q1

2022/FY

2022/Q9

2022/H1

2022/Q1

2021/FY

2021/Q9

Total Revenue

+46.13%546.65M

+38.73%190.28M

+28.43%1.06B

+22.13%692.57M

+31.07%374.09M

+20.02%137.16M

+138.97%824.88M

+222.88%567.08M

+1253.60%285.42M

+13.65%114.28M

-66.52%345.18M

-75.17%175.63M

-96.65%21.09M

-79.86%100.55M

-76.02%1.03B

-77.08%707.40M

-69.45%629.79M

+6.98%499.36M

+23086.49%4.30B

+54286.51%3.09B

Operating Revenue

+46.13%546.65M

+38.73%190.28M

+28.43%1.06B

+22.13%692.57M

+31.07%374.09M

+20.02%137.16M

+138.97%824.88M

+222.88%567.08M

+1253.60%285.42M

+13.65%114.28M

-66.52%345.18M

-75.17%175.63M

-96.65%21.09M

-79.86%100.55M

-76.02%1.03B

-77.08%707.40M

-69.45%629.79M

+6.98%499.36M

+23086.49%4.30B

+54286.51%3.09B

Cost of Revenue

-71.84%-133.19M

-52.72%-36.26M

-6.42%-260.13M

+8.50%-133.86M

+21.13%-77.51M

+48.64%-23.74M

+79.98%-244.43M

+15.30%-146.28M

+87.68%-98.27M

+29.08%-46.23M

-0.29%-1.22B

+28.54%-172.72M

-154.31%-797.57M

+56.10%-65.19M

+6.17%-1.22B

+76.91%-241.69M

+49.85%-313.62M

+33.73%-148.47M

-9301.40%-1.30B

-207805.96%-1.05B

Cost of Goods Sold

-71.84%-133.19M

----

-6.42%-260.13M

----

+21.13%-77.51M

----

+79.98%-244.43M

----

+87.68%-98.27M

----

-0.29%-1.22B

----

-154.31%-797.57M

----

+6.17%-1.22B

----

+49.85%-313.62M

----

-9301.40%-1.30B

----

Gross Profit

+39.41%413.47M

+35.80%154.02M

+37.70%799.26M

+32.78%558.71M

+58.47%296.58M

+66.67%113.42M

+166.26%580.45M

+14344.25%420.79M

+124.10%187.15M

+92.41%68.05M

-369.45%-876.02M

-99.37%2.91M

-345.59%-776.49M

-89.92%35.37M

-106.22%-186.61M

-77.16%465.71M

-77.98%316.17M

+44.57%350.88M

+63231.92%3.00B

+39339.44%2.04B

Operating Expense

-13.22%-446.38M

-8.97%-190.00M

+7.97%-915.39M

-2.77%-633.97M

+1.49%-394.25M

+11.73%-174.36M

+23.54%-994.68M

+62.84%-616.86M

+36.22%-400.22M

+27.11%-197.54M

+2.32%-1.30B

-15.53%-1.66B

-12.64%-627.53M

-5.39%-271.00M

-9.32%-1.33B

-72.13%-1.44B

+17.63%-557.12M

+12.13%-257.14M

-130.58%-1.22B

-270.02%-834.69M

Selling Expenses

-25.80%-196.68M

-38.21%-81.08M

-12.92%-416.73M

-41.41%-277.22M

-39.00%-156.34M

-25.92%-58.66M

-4.43%-369.05M

-1.24%-196.04M

+12.70%-112.48M

+15.27%-46.59M

-32.55%-353.40M

-29.84%-193.63M

-44.93%-128.84M

-60.25%-54.98M

-151.95%-266.61M

-132.61%-149.14M

-157.07%-88.90M

-378.52%-34.31M

-538.92%-105.82M

-689.03%-64.11M

Administrative Expenses

-9.37%-85.04M

-2.30%-35.77M

+10.93%-173.11M

+6.29%-110.05M

+11.41%-77.76M

+5.66%-34.97M

+33.99%-194.36M

+37.57%-117.43M

+37.33%-87.78M

+38.78%-37.07M

-5.89%-294.45M

+11.11%-188.09M

-0.30%-140.05M

+5.54%-60.55M

-19.95%-278.07M

-49.97%-211.61M

-54.35%-139.63M

-330.93%-64.10M

-179.71%-231.81M

-178.05%-141.11M

Research and Development Expenses

-5.21%-155.49M

+1.79%-71.41M

+24.77%-313.04M

+17.48%-224.67M

+20.50%-147.79M

+24.84%-72.71M

+34.78%-416.12M

+41.02%-272.27M

+45.06%-185.90M

+35.40%-96.75M

+18.02%-637.99M

+15.92%-461.67M

-4.45%-338.37M

+4.70%-149.77M

+11.43%-778.26M

+16.27%-549.07M

+41.23%-323.97M

+41.75%-157.16M

-105.08%-878.72M

-271.09%-655.77M

Impairment and Provision

+25.78%-9.17M

+56.90%-4.66M

+17.40%-12.52M

-9.52%-26.18M

+12.12%-12.36M

+28.24%-10.80M

-0.70%-15.15M

+97.02%-23.90M

+30.59%-14.06M

-16.94%-15.05M

-71.43%-15.05M

-50.46%-801.12M

-338.13%-20.26M

-108.88%-12.87M

-381.20%-8.78M

-11281.90%-532.45M

-6148.65%-4.62M

-76937.50%-6.16M

-366.50%-1.82M

---4.68M

-Impairment Losses of Other Assets

+25.78%-9.17M

+56.90%-4.66M

+17.40%-12.52M

-9.52%-26.18M

+12.12%-12.36M

+28.24%-10.80M

-0.70%-15.15M

+97.02%-23.90M

+30.59%-14.06M

-16.94%-15.05M

-71.43%-15.05M

-50.46%-801.12M

-338.13%-20.26M

-108.88%-12.87M

-381.20%-8.78M

-11281.90%-532.45M

-6148.65%-4.62M

-76937.50%-6.16M

-366.50%-1.82M

---4.68M

Revaluation Surplus

----

+7.93%2.91M

----

+157.01%4.10M

----

+229.10%2.70M

----

+53.23%-7.19M

----

-129.16%-2.09M

----

-379.50%-15.37M

----

+56.11%7.17M

----

-82.25%5.50M

----

+670.43%4.59M

----

+209.47%30.98M

-Changes in The Fair Value of Other Assets

----

+7.93%2.91M

----

+157.01%4.10M

----

+229.10%2.70M

----

+53.23%-7.19M

----

-129.16%-2.09M

----

-379.50%-15.37M

----

+56.11%7.17M

----

-82.25%5.50M

----

+670.43%4.59M

----

+209.47%30.98M

Profit from Asset Sales

----

+281.80%42.96K

----

--84.72K

----

-163.08%-23.63K

----

--37.46K

----

Special Items of Operating Income

-36.67%60.45M

-71.99%14.16M

+1379.74%160.39M

+601.99%115.54M

+355.24%95.46M

+175.68%50.55M

-92.35%10.84M

-113.76%-23.02M

-160.73%-37.40M

-230.88%-66.79M

-5.26%141.72M

+44.00%167.28M

-19.13%61.58M

+31.82%51.03M

+16.99%149.58M

+204.12%116.16M

+78.83%76.15M

+499.30%38.72M

+4.19%127.85M

+13.35%38.20M

Operating Profit

+1347.15%27.54M

-98.20%-25.08M

+110.97%44.26M

+113.15%29.72M

+99.12%-2.21M

+93.62%-12.66M

+80.18%-403.39M

+84.89%-225.94M

+81.34%-250.47M

-6.28%-198.26M

-48.69%-2.04B

-73.96%-1.50B

-714.58%-1.34B

-242.43%-186.54M

-171.60%-1.37B

-169.67%-859.78M

-120.54%-164.80M

+391.65%130.97M

+576.88%1.91B

+751.39%1.23B

Financing Income

-21.70%13.57M

-22.37%7.84M

-57.78%34.77M

-53.43%23.90M

-67.97%17.33M

-56.90%10.10M

-31.74%82.35M

-31.75%51.32M

-38.87%54.09M

+4.06%23.43M

-46.75%120.64M

+68.53%75.20M

-36.10%88.49M

+59.89%22.52M

+184.45%226.57M

-28.28%44.62M

+235.72%138.49M

-37.03%14.08M

+151.10%79.65M

+390.56%62.22M

Financing Cost

-1.87%-35.07M

+44.77%-7.19M

+4.77%-57.29M

+23.21%-36.40M

-4.87%-34.42M

+11.29%-13.02M

+6.50%-60.16M

-3.15%-47.41M

-11.65%-32.82M

-67.46%-14.67M

-53.82%-64.34M

-66.83%-45.96M

-92.87%-29.40M

+7.22%-8.76M

+23.21%-41.83M

-121.50%-27.55M

-125.86%-15.24M

-465.51%-9.44M

-98.09%-54.48M

---12.44M

Pretax Profit

+131.28%6.04M

-107.18%-34.38M

+105.70%21.74M

+103.76%8.49M

+91.58%-19.30M

+90.51%-16.59M

+80.74%-381.20M

+84.50%-225.70M

+82.14%-229.20M

+12.76%-174.88M

-67.14%-1.98B

-125.10%-1.46B

-2988.28%-1.28B

-265.82%-200.47M

-161.13%-1.18B

-150.13%-646.85M

-104.97%-41.56M

+867.49%120.90M

+588.30%1.94B

+833.63%1.29B

Special Items of Pretax Income

----

+63.39%-40.92K

----

+82.44%-504.64K

----

-6398.83%-111.76K

----

+92.94%-2.87M

----

+99.98%-1.72K

----

-3128.89%-40.70M

----

-729.24%-8.12M

----

+74.07%-1.26M

----

-323.52%-979.00K

----

-703.60%-4.86M

Tax

-216.17%-6.76M

----

+348.68%6.14M

----

+703.53%5.82M

----

-121.54%-2.47M

----

-182.82%-964.00K

----

-94.78%11.45M

----

-97.98%1.16M

----

+838.17%219.24M

----

-42.57%57.60M

----

---29.70M

----

Net Profit

+94.65%-721.00K

-250.13%-40.42M

+107.26%27.87M

+106.36%14.44M

+94.14%-13.49M

+93.40%-11.55M

+80.50%-383.67M

+84.38%-227.20M

+82.05%-230.16M

-2.75%-174.88M

-103.93%-1.97B

-197.72%-1.45B

-8092.09%-1.28B

-248.91%-170.20M

-150.59%-964.76M

-136.64%-488.68M

-98.29%16.04M

+825.59%114.30M

+580.81%1.91B

+858.36%1.33B

Profit from Continuing Operations

+94.65%-721.00K

-250.13%-40.42M

+107.26%27.87M

+106.36%14.44M

+94.14%-13.49M

+93.40%-11.55M

+80.50%-383.67M

+84.38%-227.20M

+82.05%-230.16M

-2.75%-174.88M

-103.93%-1.97B

-197.72%-1.45B

-8092.09%-1.28B

-248.91%-170.20M

-150.59%-964.76M

-136.64%-488.68M

-98.29%16.04M

+825.59%114.30M

+580.81%1.91B

+858.36%1.33B

Minority Interests

----

+99.01%-4.79M

+98.98%-4.79M

+98.91%-4.79M

+84.38%-4.79M

-776.08%-484.70M

-3192.65%-469.89M

-11683.23%-440.74M

-330.62%-30.65M

-657.48%-55.33M

---14.27M

--3.81M

-334.55%-7.12M

---7.30M

----

Net Income to Parent Company

+94.65%-721.00K

-250.13%-40.42M

+107.36%27.87M

+106.49%14.44M

+94.02%-13.49M

+93.21%-11.55M

+74.45%-378.88M

+77.42%-222.41M

+73.22%-225.37M

-21.89%-170.10M

-63.04%-1.48B

-107.63%-985.03M

-6975.54%-841.43M

-214.94%-139.55M

-147.51%-909.43M

-135.57%-474.41M

-98.69%12.24M

+960.23%121.41M

+582.65%1.91B

+858.36%1.33B

Net Income to Common Stockholders

+94.65%-721.00K

-250.13%-40.42M

+107.36%27.87M

+106.49%14.44M

+94.02%-13.49M

+93.21%-11.55M

+74.45%-378.88M

+77.42%-222.41M

+73.22%-225.37M

-21.89%-170.10M

-63.04%-1.48B

-107.63%-985.03M

-6975.54%-841.43M

-214.94%-139.55M

-147.51%-909.43M

-135.57%-474.41M

-98.69%12.24M

+960.23%121.41M

+582.65%1.91B

+858.36%1.33B

Basic EPS

+100.00%0.00

-220.00%-0.16

+107.19%0.11

+106.67%0.06

+94.51%-0.05

+92.75%-0.05

+74.54%-1.53

+77.44%-0.90

+73.31%-0.91

-21.05%-0.69

-63.32%-6.01

-107.81%-3.99

-6920.00%-3.41

-216.33%-0.57

-147.55%-3.68

-135.62%-1.92

-98.68%0.05

+916.67%0.49

+550.00%7.74

+791.03%5.39

Diluted EPS

+100.00%0.00

-220.00%-0.16

+107.19%0.11

+106.67%0.06

+94.51%-0.05

+92.75%-0.05

+74.54%-1.53

+77.44%-0.90

+73.31%-0.91

-21.05%-0.69

-63.32%-6.01

-107.81%-3.99

-6920.00%-3.41

-216.33%-0.57

-147.55%-3.68

-135.62%-1.92

-98.68%0.05

+916.67%0.49

+550.00%7.74

+791.03%5.39

Deadline

Jun 30, 2026

Mar 31, 2026

Dec 31, 2025

Sep 30, 2025

Jun 30, 2025

Mar 31, 2025

Dec 31, 2024

Sep 30, 2024

Jun 30, 2024

Mar 31, 2024

Dec 31, 2023

Sep 30, 2023

Jun 30, 2023

Mar 31, 2023

Dec 31, 2022

Sep 30, 2022

Jun 30, 2022

Mar 31, 2022

Dec 31, 2021

Sep 30, 2021

Accounting Standard

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

HKAS

CAS (2007)

Audit Opinions

Unqualified opinion

	2026/H1	2026/Q1	2025/FY	2025/Q9	2025/H1	2025/Q1	2024/FY	2024/Q9	2024/H1	2024/Q1	2023/FY	2023/Q9	2023/H1	2023/Q1	2022/FY	2022/Q9	2022/H1	2022/Q1	2021/FY	2021/Q9

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More

牛牛課堂

Oct 13, 2025 18:05

[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?

Food流油

Apr 14, 2025 15:43

"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"